Hemispherx Biopharma Reaches Agreement with Avrio Biopharmaceuticals for the Accelerated Production of Ampligen®

by Barry101 | Jul 27, 2016 | Press Release

PHILADELPHIA, July 27, 2016 — Hemispherx Biopharma (NYSE MKT:HEB) (“Hemispherx” or the “Company”) announced today that it has reached an agreement with Avrio Biopharmaceuticals (“Avrio”), Irvine California, to serve as an...

Hemispherx Announces First Shipment of Rintatolimod (Ampligen®) to Early Access Program in Europe

by Barry101 | Jul 25, 2016 | Press Release

PHILADELPHIA, July 25, 2016 — Hemispherx Biopharma (NYSE MKT:HEB) announced today that the first order of rintatolimod (Ampligen®) for the Early Access Program (EAP) in Europe has been shipped with receipt confirmed on July 22. On May 23, 2016, the Company...

Hemispherx Biopharma Bolsters Manufacturing and Scientific Capabilities Through Key Consulting and Management Appointments

by Barry101 | Jul 19, 2016 | Press Release

Promotes Carol Smith, Ph.D., to Manager of Quality as Part of Manufacturing OptimizationRetains Step Change Pharma as Advisor to Strengthen Manufacturing and Technical InfrastructureRetains Former Director of Research & Development, Joseph C. Horvath, M.D., as...

Hemispherx Outlines Key Elements of Strategic Growth Plan and Commitment to Transparency

by Barry101 | Jul 14, 2016 | Press Release

PHILADELPHIA, July 14, 2016 — Hemispherx Biopharma (NYSE:HEB) (“Hemispherx” or the “Company”) today announced key elements of its strategic growth plan as well as additional measures being implemented under the Company’s commitment...

Hemispherx Updates the Status of the Alferon® Manufacturing Facility

by Barry101 | Jul 11, 2016 | Press Release

PHILADELPHIA, July 11, 2016 — Hemispherx Biopharma (NYSE MKT:HEB) in response to various questions about the status of the work to repair damage to our Alferon®  Manufacturing  facility caused by the flood of January 5, 2016 is pleased to provide...